Generic Name and Formulations:
Tazarotene 0.1%; foam.
Stiefel Laboratories, Inc.
Indications for FABIOR:
Cleanse and dry affected area. Apply a thin layer to affected areas on face and/or upper trunk once daily in the PM. Women of childbearing potential: begin therapy during normal menses.
Obtain reliable negative pregnancy test within 2 weeks before starting therapy; use effective contraception during therapy. Do not use on broken or eczematous skin. History of local hypersensitivity. Photosensitivity. History of skin cancer. Avoid eyes, lips, mouth, mucous membranes, sun and UV light; use adequate sun protection. Increased irritation in extreme weather. Discontinue if excessive local irritation occurs. Flammable. Nursing mothers: not recommended.
Cumulative irritant effect with concomitant other topical acne therapy; use caution. Avoid use until the effects of strong topical drying agents have subsided. Concomitant oxidizing agents (eg, benzoyl peroxide) may cause tazarotene degradation and reduce efficacy; apply at different times of the day (eg, AM & PM) if combination treatment is needed.
Application site reactions (eg, irritation, dryness, erythema, exfoliation, pain, photosensitivity, pruritus, dermatitis).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Nicotinamide and Cancer
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML